Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
methylphenidate + K-PAX Synergy
- Development stage
- Unknown
- Lead developer
- K-PAX Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
KPAX002 (methylphenidate + K-PAX Synergy) is an investigational combination therapy developed by K-PAX Pharmaceuticals for the treatment of Chronic Fatigue Syndrome (CFS), Myalgic Encephalomyelitis (ME), and Gulf War Illness (GWI). The drug consists of a low-dose, extended-release formulation of methylphenidate hydrochloride, a central nervous system stimulant, co-administered with a proprietary broad-spectrum micronutrient supplement (K-PAX Synergy) designed to support mitochondrial function. The therapeutic rationale is that the nutrient formula addresses underlying mitochondrial dysfunction and oxidative stress, thereby enhancing the efficacy and reducing the side effects of the stimulant component. KPAX002 has been evaluated in Phase II clinical trials, demonstrating improvements in fatigue and cognitive symptoms in patients with CFS and GWI.
- Brand names
- Ritalin
- Other names
- Methylphenidate Hydrochloride + K-PAX SynergyMethylphenidate + CFS Nutrient FormulaMethylphenidate + GWI Nutrient Formula
02
Targets
DAT (Dopamine plasma membrane transport protein)NET (Norepinephrine Transporter)
Beyond the preview
Go deeper on methylphenidate + K-PAX Synergy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on methylphenidate + K-PAX Synergy.